Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

OBJECTIVES: Methotrexate is considered to be first-line therapy for rheumatoid arthritis (RA). However, a substantial proportion of treated patients do not achieve the desired goals of therapy. This analysis aimed to identify predictors of insufficient response to methotrexate in patients with early...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, van Vollenhoven, Ronald F, Florentinus, Stefan, Chen, Su, Suboticki, Jessica L, Kavanaugh, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225797/
https://www.ncbi.nlm.nih.gov/pubmed/30076156
http://dx.doi.org/10.1136/annrheumdis-2018-213502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225797/
https://www.ncbi.nlm.nih.gov/pubmed/30076156
http://dx.doi.org/10.1136/annrheumdis-2018-213502

Ejemplares similares